Leflunomide

Spezifikationen

75706-12-6CAS-Nummer

616-254-6EG-Nummer

5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamideIUPAC-Name

C12H9F3N2O2Chemische Formel

270.21 g/molMolekulargewicht

leflunomide; 75706-12-6; Arava; Leflunomida; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; Leflunomidum; HWA-486; Repso; leflunomide medac; SU101; Leflunomide teva; SU-101; DTXSID9023201; Leflunomide winthrop; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; SULOL; Leflunomide ratiopharm; 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; NSC-677411; NSC-759864; G162GK9U4W; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; L04AA13; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; CHEBI:6402; DTXCID103201; NSC677411; N-(4-(TRIFLUOROMETHYL)PHENYL) 5 METHYLISOXAZOLE-4-CARBOXAMIDE; HWA486; 5-methyl-N-(4-(trifluoromethyl)phenyl)-1,2-oxazole-4-carboxamide; N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; RefChem:55458; 616-254-6; lefunamide; HWA 486; Leflunomidum [INN-Latin]; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; Arava (TN); 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; MFCD00867593; CHEMBL960; MLS000069648; NCGC00015610-02; SMR000058209; CAS-75706-12-6; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); Lefunomide [Inn-Spanish]; Leflunomide [INN]; RS-34821; HSDB 7289; SR-01000000191; UNII-G162GK9U4W; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); Arabloc; Leflunomide CRS; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Prestwick_87; Leflunomide [USAN:USP:INN:BAN]; SU 101; Leflunomide (Standard); Spectrum_000322; LEFLUNOMIDE [MI]; Opera_ID_1709; Prestwick0_000772; Prestwick1_000772; Prestwick2_000772; Prestwick3_000772; Spectrum5_000850; LEFLUNOMIDE [JAN]; Lopac-L-5025; LEFLUNOMIDE [HSDB]; LEFLUNOMIDE [USAN]; L 5025; LEFLUNOMIDE [VANDF]; SCHEMBL5057; LEFLUNOMIDE [MART.]; BIDD:PXR0189; Lopac0_000649; BSPBio_000844; KBioSS_000802; LEFLUNOMIDE [USP-RS]; LEFLUNOMIDE [WHO-DD]; AP-501/42475599; Leflunomide, Immunosuppressant; MLS001076267; DivK1c_000916; Leflunomide (JAN/USP/INN); SPECTRUM1503927; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; SPBio_002783; LEFLUNOMIDE [EMA EPAR]; BPBio1_000930; GTPL6825; orb1224060; orb1309564; Leflunomide - Bio-X trade mark; HMS502N18; HY-B0083R; KBio1_000916; KBio2_000802; KBio2_003370; KBio2_005938; LEFLUNOMIDE [EP IMPURITY]; LEFLUNOMIDE [ORANGE BOOK]; NINDS_000916; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; GLXC-06853; HMS1570K06; HMS1922M06; HMS2090O12; HMS2097K06; HMS2235C07; HMS3262A19; HMS3268D12; HMS3371F21; HMS3414P03; HMS3654F07; HMS3673M17; HMS3678N21; HMS3714K06; HMS3865I13; HMS5079K21; HMS6019D06; LEFLUNOMIDE [EP MONOGRAPH]; Pharmakon1600-01503927; LEFLUNOMIDE [USP MONOGRAPH]; ALBB-019233; HY-B0083; MSK10662; PXB98723; Tox21_110182; Tox21_301873; Tox21_500649; BDBM50054601; DL-433; EBC-08359; NSC759864; s1247; STL426823; AKOS000265193; Tox21_110182_1; AC-6796; CCG-204736; CS-1781; DB01097; FL16204; KS-1076; Leflunomide for peak identification CRS; LP00649; NSC 677411; NSC 759864; SB17287; SDCCGSBI-0050629.P003; IDI1_000916; NCGC00015610-01; NCGC00015610-03; NCGC00015610-04; NCGC00015610-05; NCGC00015610-06; NCGC00015610-07; NCGC00015610-08; NCGC00015610-09; NCGC00015610-10; NCGC00015610-11; NCGC00015610-12; NCGC00015610-13; NCGC00015610-14; NCGC00015610-17; NCGC00015610-18; NCGC00015610-28; NCGC00015610-30; NCGC00022625-03; NCGC00022625-04; NCGC00022625-05; NCGC00022625-06; NCGC00022625-07; NCGC00022625-08; NCGC00255370-01; NCGC00261334-01; BM164612; ST079287; Leflunomide 100 microg/mL in Acetonitrile; AB00052389; EU-0100649; L0250; L1817; NS00003822; SW196399-3; C07905; D00749; EN300-119495; MLS-0003109.0001; AB00052389-17; AB00052389-18; AB00052389_19; AB00052389_21; F358076; Q248550; SR-01000000191-2; SR-01000000191-4; SR-01000000191-7; BRD-K78692225-001-03-9; BRD-K78692225-001-11-2; BRD-K78692225-001-22-9; BRD-K78692225-001-23-7; BRD-K78692225-001-24-5; Z228668542; 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole; 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole; Leflunomide Working Standard (Secondary Reference Standard); Leflunomide, European Pharmacopoeia (EP) Reference Standard; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide; 5-Methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4- carboxamide; 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide; N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide; (5-methylisoxazol-4-yl)-N-[4-(trifluoromethyl)phenyl]carboxamide; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; Leflunomide, United States Pharmacopeia (USP) Reference Standard; Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material; Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard; Leflunomide MicronizedSynonyme